ARCHIVES

“Significant changes should be made to reduce redundancy, streamline operations, promote collaboration, and optimize productivity.”

This article is from The Cancer Letter archive.

Vol. 21 No. 28 | July 14, 1995

Download PDF Visit The Full Archive

Related Articles

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

PBS Runs Misleading Lung Screening Claim; Reporter and Subject on Mount Sinai Faculty

October 11, 2013

President, Congress, Cancer Letter Take Off

August 22, 1986

NCI Receives 165 SBIR Grant Applications; Combines With Solid Contracts, No More Fiascos Are Expected

June 14, 1985

In Brief: Jordan To Join MD Anderson Cancer Center

July 25, 2014

NCI Critics Take Their Best Shots, Seek New Emphasis On Prevention At Kennedy Hearings

March 16, 1979